Warm congratulations on the establishment of our company’s first academician workstation!!!

    Our company has won the recognition of the leadership group of the Shandong Provincial Department of Science and Technology with strong technical strength, industry experience, and rich production experience, and has been awarded the company’s first academician workstation.
    As our company’s first academician workstation, it will focus on achievements transformation, improving the quality of medical industry practitioners, and serving the development of the medical industry. The construction of talent teams and other aspects have contributed to the new development of the medical industry. Our academician workstation will focus on accelerating the transformation of achievements and promoting the innovative development of our medical industry; Optimize the talent pool and enhance the independent innovation capability of the medical industry; Provide expert navigation.
    Academician Liu Xinheng created the cancer targeting gene virus therapy (CTGVT) strategy and its dual gene CTGVT-DG strategy in 2001, and conducted industrial research and development on them. In addition, Academician Liu Xinyuan combined the CTGVT-DG strategy with nanotechnology. For example, on oncolytic adenovirus OncoAd gene carrying anti-cancer genes, Ca2HPO4 was first encapsulated, followed by two layers of liposomes. This allows for better tumor treatment effects by intravenous injection without the need for intratumoral injection.
    After signing the contract, Academician Liu Xinheng expressed the hope that both sides will continue to deepen cooperation, work together, and effectively improve the service capabilities of the medical industry, providing world-class services for the medical industry.
    In addition, Academician Liu Xinyuan combined the CTGVT-DG strategy with nanotechnology. For example, on oncolytic adenovirus OncoAd gene carrying anti-cancer genes, Ca2HPO4 was first encapsulated, followed by two layers of liposomes. This allows for better tumor treatment effects by intravenous injection without the need for intratumoral injection.
    After signing the contract, Academician Liu Xinheng expressed the hope that both sides will continue to deepen cooperation, work together, and effectively improve the service capabilities of the medical industry, providing world-class services for the medical industry.